Runimotamab

• Description:

  Runimotamab (RG-6194) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1][2].

• Product Name Alternative:

  BTRC-4017A; RG-6194

• UNSPSC:

  12352203

• Target:

  CD3; EGFR

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/runimotamab.html

• Purity:

  99.00

• Solubility:

  10 mM in DMSO

• Smiles:

  [Runimotamab]

• Molecular Weight:

  (146.081 kDa)

• References & Citations:

  [1]Shanu Modi, et al., Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC) . Cancer Res 15 April 2025; 85 (8_Supplement_2) |[2]Michal Rudnik, et al., Abstract 2747: Combined investigation of anti-tumor efficacy and liver safety of bispecific T cell engagers in immune-competent high-throughput co-culturing platform. Cancer Res 1 April 2023; 83 (7_Supplement) : 2747.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 1

• CAS Number:

  [2361325-98-4]